CHPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHPT is not a good buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term momentum and improving hedge fund interest, but the overall setup is still mixed: analysts are lowering targets, options sentiment is cautious, and the technicals show the stock is overbought after a recent move. Since the investor is impatient and not waiting for an ideal entry, the current price still looks like a hold rather than an attractive long-term buy.
CHPT is trading at 7.88, just above the prior close and near short-term resistance. MACD is positive and expanding, which supports near-term momentum, but RSI_6 at 82.192 signals the stock is overbought. Moving averages are converging, suggesting the trend is not yet strongly established. Key levels show pivot at 6.909, resistance at R1 7.745 and R2 8.262, with support at S1 6.072. Price is already above R1, but the overbought RSI makes this look extended rather than a clean entry. The expected path data also implies only modest upside over the next week and month.
["Hedge funds are buying, with buying amount up 212.50% over the last quarter.", "Recent news around Revel and Voltera merging to build a fast-charging infrastructure platform for autonomous vehicles and electric fleets supports broader EV charging industry interest.", "MACD is positive and expanding, showing near-term momentum."]
["Analysts have been cutting price targets repeatedly across UBS, B. Riley, Roth Capital, TD Cowen, RBC, and JPMorgan.", "Several firms cite light guidance, demand uncertainty, and hardware margin pressure.", "RSI is deeply overbought, which makes the current price look stretched.", "Options positioning is defensive with put open interest exceeding call open interest.", "No recent congress trading data and no notable insider buying signal to reinforce conviction."]
No usable latest-quarter financial snapshot was provided due to an error, so a full quarter-by-quarter assessment is not available. Based on analyst commentary, the latest reported quarter appears to have been slightly better than estimates on revenue, but guidance for Q1 was below expectations. Management and some analysts pointed to new product launches as a future growth driver, yet near-term demand remains sluggish and gross margins are under pressure. Latest quarter season: Q4 earnings period.
Wall Street is mostly neutral to negative on CHPT. Recent ratings were mainly Neutral, Hold, Sector Perform, and Underweight, while price targets were cut from prior levels: UBS to $7, B. Riley to $6, Roth to $6.50, TD Cowen to $7, RBC to $6.50, and JPMorgan to $5. The pro view is that results were somewhat solid and new products may help later, but the con view dominates: guidance is light, demand is uncertain, and margins remain challenged. Overall, the analyst trend is clearly bearish on expectations, even if not outright bearish on the rating label.
